Randomized trial · people
Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Head to head over 56 weeks, exenatide ER 2.0 mg lowered HbA1c and weight less than semaglutide 1.0 mg, with fewer gut side effects but more injection-site reactions.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 813
- Published
- 2018
- Journal
- Diabetes Care
What they tested
The team tested whether once-weekly semaglutide 1.0 mg lowers blood sugar as well as or better than exenatide extended release (ER) 2.0 mg in people with type 2 diabetes.
How the study was done
A randomized, open-label, phase 3a trial (everyone knew which drug they got) in 813 adults with type 2 diabetes already on diabetes pills, split evenly between semaglutide 1.0 mg and exenatide ER 2.0 mg for 56 weeks. The main measure was the change in HbA1c, a 3-month average of blood sugar.

Model. Individual results vary.
What they found
From a starting HbA1c of 8.3%, the exenatide ER arm dropped 0.9% and the semaglutide arm dropped 1.5%, an estimated gap of -0.62% in favor of semaglutide. Body weight, 95.8 kg at the start, fell 1.9 kg with exenatide ER and 5.6 kg with semaglutide. An HbA1c under 7.0% was reached by 40% on exenatide ER and 67% on semaglutide. Stomach and gut side effects hit 33.3% on exenatide ER and 41.8% on semaglutide, but reactions where the shot went in showed up in 22.0% of the exenatide ER arm, against 1.2% of the semaglutide arm.
What it doesn’t show
The trial was open-label and tested a single dose of each drug, only in people whose diabetes was not controlled on pills. It ran for 56 weeks, so it does not show longer-term results.
The paper
Ahmann et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care. 2018.
The compounds
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.